Skip to main content
TipRanks
Go Ultimate75% OFF

Optimi Health (OPTI) AI Stock Analysis

42 Followers
TSE:OPTI

Optimi Health

(CNQX:OPTI)

Select Model
Rating:37Underperform
Price Target:CAD 3.00â–²(30.43% Upside)
Action:reiterated
Date:11/03/26

The overall score of 37 reflects a company in severe financial distress with a uniformly negative outlook across all evaluated components. The most significant factor is the deteriorating financial performance, marked by collapsing revenue, deeply negative margins, and a high cash burn rate that is rapidly eroding equity. This is compounded by a bearish technical trend with the stock in a sustained downtrend and deeply oversold conditions. The negative P/E ratio and lack of dividends offer no valuation support. The company faces high risk of financial distress without a significant capital infusion or operational turnaround.

Positive Factors
Equity CushionThe sizeable equity base relative to assets provides some balance-sheet cushioning while the company develops its operations. Although losses and rising leverage weaken this support, the current capital position may provide greater resilience than a business already facing asset-liability stress.
Negative Factors
Recent Revenue ContractionThe recent revenue decline is concerning because it reverses earlier growth while leaving the company with a very small commercial base. Lower sales reduce operating leverage, make fixed costs harder to absorb, and increase the challenge of reaching a sustainable scale within the next several quarters.

Optimi Health (OPTI) vs. iShares MSCI Canada ETF (EWC)

-80%-60%-40%-20%0%20%40%TSE:OPTI-78.10%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CAD 13.17M
Dividend Yield
―
Average Volume (3M)
5,100
Price to Earnings (P/E)
-1.2
Beta (1Y)
1.31
Revenue Growth
―
EPS Growth
―
Country
Canada
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Optimi Health Business Overview & Revenue Model

Company Description

Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and dis...

How the Company Makes Money

Optimi Health makes money primarily by selling mushroom-related products and services across a few core channels: (1) Product sales from cultivation and processing: Revenue is generated through the production and sale of functional mushrooms and, whe...

Optimi Health Financial Statement Overview

Summary

Financial health is critically weak. The company is pre-revenue with a 24% TTM revenue decline, gross margins have collapsed to -1,323%, and net losses are accelerating, eroding shareholder equity. The debt-to-equity ratio has spiked to 1.86, adding significant financial risk. The only mitigating factor is a 61% improvement in free cash flow, suggesting cost-cutting, but this does not offset the severe operational and solvency concerns.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Sep 2022Sep 2021
Income Statement
Total Revenue175.67K426.30K389.85K181.09K80.72K0
Gross Profit-3.68M-2.07M270.91K-157.04K53.92K-47.12K
EBITDA-4.93M-2.23M-4.74M-4.42M-7.03M-5.95M
Net Income-6.90M-3.71M-6.04M-5.19M-7.38M-6.04M
Balance Sheet
Total Assets25.86M15.21M14.55M16.49M16.82M23.46M
Cash, Cash Equivalents and Short-Term Investments13.07M1.15M103.66K1.34M1.89M12.43M
Total Debt5.14M6.68M2.75M1.71M157.58K250.84K
Total Liabilities8.22M8.64M4.98M3.28M797.66K2.40M
Stockholders Equity17.64M6.57M9.58M13.21M16.02M21.07M
Cash Flow
Free Cash Flow-5.31M-2.72M-4.43M-4.41M-11.73M-10.96M
Operating Cash Flow-5.20M-2.63M-4.28M-3.60M-4.58M-6.02M
Investing Cash Flow-109.68K-88.38K-154.02K-706.02K-3.15M-9.19M
Financing Cash Flow18.29M3.76M3.19M3.76M1.19M19.18M

Optimi Health Technical Analysis

Technical Analysis SentimentNegative
Last Price2.30

Price Trends

50DMA4.91Negative
100DMA5.79Negative
200DMA7.28Negative

Market Momentum

MACD-0.63Negative
RSI20.75Positive
STOCH2.75Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:OPTI, the sentiment is Negative. The current price of 2.30 is below the 20-day moving average (MA) of 3.27, below the 50-day MA of 4.91, and below the 200-day MA of 7.28, indicating a bearish trend. The MACD of -0.63 indicates Negative momentum. The RSI at 20.75 is Positive, neither overbought nor oversold. The STOCH value of 2.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:OPTI.

Optimi Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:OPTI against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSE:LABSTSE:LABS55NeutralCAD 25.63M-9.23-7.66%―-9.31%66.84%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:ROMJTSE:ROMJ49NeutralCAD 23.65M-5.25-10.97%―16.91%-244.25%
TSE:AVCNTSE:AVCN48NeutralCAD 11.42M-3.86-65.40%―-3.32%-34.15%
TSE:DOSETSE:DOSE39UnderperformCAD 13.09M-4.0442.51%―-19.31%34.45%
TSE:PCLOTSE:PCLO39UnderperformCAD 6.54M-1.8728.59%―0.90%57.73%
TSE:OPTITSE:OPTI37UnderperformCAD 13.17M-1.18-84.23%―――

* Healthcare Sector Average

Performance Comparison

0%100%200%TSE:OPTITSE:DOSETSE:LABSTSE:PCLOTSE:ROMJTSE:AVCNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
TSE:OPTI and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:OPTIOptimi Health Corp.2.30-8.35-78.40%
TSE:DOSERapid Dose Therapeutics Corp0.10-0.08-44.12%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-7.69%
TSE:PCLOPharmacielo0.04-0.01-22.22%
TSE:ROMJRubicon Organics 0.35-0.10-22.22%
TSE:AVCNAvicanna Inc0.09-0.15-64.58%

Optimi Health Corporate Events

Business Operations and StrategyExecutive/Board Changes

Optimi Health Sets Up Australian Subsidiary to Drive Psychedelic Drug Distribution

Positive
Oct 26, 2026

Optimi Health has created a wholly owned subsidiary, Optimi Australia Pty Ltd, to serve as its dedicated distribution and business development arm in Australia. The new entity will oversee sales, distribution, and prescriber relationships for the com...

Business Operations and StrategyProduct-Related Announcements

Optimi Health Readies MDMA Supply for Global PTSD Trials and Australian Market

Positive
Oct 20, 2026

Optimi Health Corp., a Vancouver-based commercial-stage pharmaceutical manufacturer, produces GMP-grade MDMA and psilocybin drug products for regulated mental health therapies. The Health Canada-licensed company supplies active pharmaceutical ingredi...

Business Operations and StrategyExecutive/Board Changes

Optimi Health Adds Veteran Finance Executive Melanie Pump to Board

Positive
Sep 29, 2026

Optimi Health has appointed experienced finance executive Melanie Pump to its Board of Directors, adding more than 25 years of leadership across technology, digital infrastructure, software, fintech and emerging growth companies. The company’s CEO hi...

Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance

Optimi Health Aligns Clinical and Commercial Psilocybin Supply With New cGMP Batch

Positive
Sep 23, 2026

Optimi Health has completed and quality released an in-house cGMP batch of 5 mg naturally derived psilocybin capsules under its Health Canada Drug Establishment Licence, intended for use in a Phase 2 trial for major depressive disorder and for commer...

Business Operations and StrategyProduct-Related Announcements

Optimi Health to Launch Phase 3 MDMA Trial for PTSD in Veterans and Frontline Workers

Positive
Sep 16, 2026

Optimi Health plans to launch a Health Canada-authorized Phase 3 clinical trial in 2027 to evaluate MDMA-assisted therapy for post-traumatic stress disorder in up to 100 veterans and frontline workers across multiple sites in Canada. Participants wil...

Business Operations and Strategy

Optimi Health to Present at H.C. Wainwright Global Investment Conference

Positive
Sep 8, 2026

Optimi Health Corp., a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, focuses on GMP-grade MDMA and botanical psilocybin therapies for mental health conditions. The company operates Health Canada-licensed, GMP-co...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

Optimi Health Sets Up US$100 Million Equity Line for Psychedelic Drug Expansion

Positive
Aug 14, 2026

Optimi Health Corp. has established a discretionary equity line of credit of up to US$100 million with Seven Knots, LLC, allowing the company to sell common shares at its own discretion, subject to pricing formulas, per-draw limits, ownership caps, a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 02, 2026